The NCT02667587 clinical trial was conducted to evaluate the efficacy of a PD-1 inhibitor nivolumab, in combination with radiation therapy and temozolomide, on newly diagnosed GBM patients with a MGMT promoter. Here, MGMT is linked to glioblastoma.